-+ 0.00%
-+ 0.00%
-+ 0.00%

Vertex Announces Program Updates For Type 1 Diabetes Portfolio; VX-264 Phase 1/2 Enrollment And Dosing Complete In Parts A And B: VX-264 Was Generally Safe And Well Tolerated; Efficacy Data Are Not Supportive Of Further Clinical Advancement

Benzinga·03/28/2025 20:13:08
Listen to the news

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement -

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 -

- Continue to progress multiple novel, research-stage immunoprotective approaches -

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio.